Featured Research

from universities, journals, and other organizations

First targeted drug for advanced stomach cancer approved

Date:
April 21, 2014
Source:
Dana-Farber Cancer Institute
Summary:
Based on results of a clinical trial, the U.S. Food and Drug Administration (FDA) approved the first targeted drug as treatment for advanced stomach cancer. A monoclonal antibody with the generic name ramucirumab, it will be sold under the name Cyramza, and is the first single-agent drug to be approved for advanced stomach cancer following chemotherapy.

Charles Fuchs, MD, MPH, director of the Gastrointestinal Cancer Center at Dana-Farber
Credit: Sam Ogden/Dana-Farber Cancer Institute

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

The FDA approval after a priority review was announced by the manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody with the generic name ramucirumab, it will be sold under the name Cyramza, and is the first single-agent drug to be approved for advanced stomach cancer following chemotherapy.

An estimated 22,290 people will be diagnosed with stomach cancer in 2014, and 10,990 will die of the disease. Advanced stomach cancer is very aggressive and difficult to treat, and previously there were no FDA-approved treatments for it.

Charles Fuchs, MD, MPH, director of the Gastrointestinal Cancer Center at Dana-Farber, led a clinical trial called REGARD. Those results, reported in 2013, showed that patients who received ramucirumab had a significant improvement in their survival and a reduced rate of cancer progression compared to a placebo. The patients had advanced or metastatic gastric cancer -- cancer of the stomach -- or cancer at the junction of the esophagus with the upper part of the stomach. In these patients the disease had progressed despite initial chemotherapy with drugs such as docetaxel in combination with 5FU and cisplatin.

"For years we have looked for new and really effective drugs for stomach cancer," said Fuchs, "We have relied on standard chemotherapies for a long time, and we've needed targeted agents based on the fundamental biology of stomach cancer."

Ramucirumab is a monoclonal antibody drug that attacks the cancer by preventing it from developing new blood vessels to nourish its growth. Such drugs are known as anti-angiogenesis agents. Ramucirumab molecules latch onto the vascular endothelial growth factor (VEGF) receptor-2 on blood vessel cells, blocking them from receiving signals the cancer cells send in an effort to recruit new blood vessels. Anti-angiogenic treatments can shrink tumors by depriving them of oxygen and other nutrients.

In the REGARD clinical trial, ramucirumab increased the median overall survival of patients with advanced stomach cancer by 37 percent -- 5.2 months versus 3.8 months for patients taking a placebo. In addition, patients taking the drug had a 62 percent increase in the length of survival before the cancer progressed -- 2.1 months versus 1.3 months for placebo.

"The benefit is modest, but it's clearly better than what we were previously doing," Fuchs explained. As in other diseases such as colon cancer, he added, new drugs provide incremental benefits "but when you chip away and develop drugs in sequence, ultimately you do have meaningful clinical improvements."

Side effects were common and similar to those associated with the placebo, although more patients on ramucirumab had high blood pressure that was easily treated. Fuchs added, "It's really impressive that an antibody which had very little side effects could provide a survival benefit."

The drug's effectiveness appears to be greater when combined with chemotherapy. A large randomized clinical trial called RAINBOW assessed a combination of ramucirumab and paclitaxel in patients with advanced cancer of the stomach or gastroesophageal junction. The study demonstrated that the combination prolonged overall survival from a median of 7.36 months to 9.63 months. The new approval of ramucirumab does not cover its use in combination therapy, but Lilly Oncology has said it will submit the RAINBOW data for an expanded approval.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "First targeted drug for advanced stomach cancer approved." ScienceDaily. ScienceDaily, 21 April 2014. <www.sciencedaily.com/releases/2014/04/140421211310.htm>.
Dana-Farber Cancer Institute. (2014, April 21). First targeted drug for advanced stomach cancer approved. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2014/04/140421211310.htm
Dana-Farber Cancer Institute. "First targeted drug for advanced stomach cancer approved." ScienceDaily. www.sciencedaily.com/releases/2014/04/140421211310.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins